Chemomab Therapeutics Calls Special Shareholder Meeting

TL;DR

Chemomab (CMMB) is holding a special shareholder meeting; proxy statement filed.

AI Summary

Chemomab Therapeutics Ltd. filed a Form 6-K on October 11, 2024, to furnish a Notice and Proxy Statement for a special general meeting of its shareholders. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is incorporated in Israel and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates upcoming corporate actions or decisions requiring shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — This is a routine filing providing notice of a shareholder meeting and does not contain new financial or operational risks.

Key Players & Entities

• Chemomab Therapeutics Ltd. (company) — Registrant
• Anchiano Therapeutics Ltd. (company) — Former Company Name
• BioCancell Ltd. (company) — Former Company Name
• 001-38807 (other) — Commission File Number
• 20241011 (date) — Filing Date

FAQ

Filing Documents

• zk2432124.htm (6-K) — 11KB
• exhibit_99-1.htm (EX-99.1) — 112KB
• exhibit_99-2.htm (EX-99.2) — 24KB
• image0.jpg (GRAPHIC) — 32KB
• image00002.jpg (GRAPHIC) — 367KB
• image2.jpg (GRAPHIC) — 600KB
• 0001178913-24-003272.txt ( ) — 1525KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") hereby furnishes the following documents: (i) Notice and Proxy Statement with respect to a special general meeting of the Company's shareholders (the "Meeting") to be held on November 18, 2024, describing the proposal to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting. (ii) Proxy Card whereby holders of American Depository Shares of the Company may vote at the Meeting without attending in person. This Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-281750 and No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: October 11, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer - 3 -

View Full Filing

View this 6-K filing on SEC EDGAR